Changes in Carbohydrate Metabolism are Related to Gut Microbiota Modification after H. Pylori Eradication

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 262-LB
Author(s):  
ISABEL CORNEJO-PAREJA ◽  
GRACIA MARÍA MARTIN-NUÑEZ ◽  
M. MAR ROCA-RODRIGUEZ ◽  
ISABEL MORENO-INDIAS ◽  
LAURA VINUELA ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Carbohydrate Metabolism ◽  
H Pylori

scholarly journals H. pylori Eradication Treatment Alters Gut Microbiota and GLP-1 Secretion in Humans

2019 ◽  
Vol 8 (4) ◽  
pp. 451 ◽  
Author(s):  
Isabel Cornejo-Pareja ◽  
Gracia Martín-Núñez ◽  
M. Roca-Rodríguez ◽  
Fernando Cardona ◽  
Leticia Coin-Aragüez ◽  
...  
Keyword(s):  
Microbial Community ◽  
Gut Microbiota ◽  
Carbohydrate Metabolism ◽  
Eradication Therapy ◽  
Amplicon Sequencing ◽  
Antibiotic Use ◽  
Metabolic Disturbances ◽  
Bifidobacterium Adolescentis ◽  
16S Rrna Amplicon Sequencing ◽  
H Pylori

Changes in the intestinal microbial community and some metabolic disturbances, including obesity and type2 diabetes, are related. Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis. Microbiota have been linked to incretin secretion. Antibiotic use causes changes in microbial diversity and composition. Our aim was to evaluate the relationship between microbiota changes and GLP-1 secretion. A prospective case-control study with a Helicobacter pylori-positive patient model involving subjects under eradication therapy (omeprazole, clarithromycin, and amoxicillin). Forty patients with H. pylori infection and 20 matched participants, but negative for H. pylori antigen. Patients were evaluated before and two months after treatment. We analyzed anthropometric measurements, carbohydrate metabolism, lipid profile, and C-reactive protein. Gut microbiota composition was analyzed through 16S rRNA amplicon sequencing (IlluminaMiSeq). Eradication treatment for H. pylori decreased bacterial richness (Chao1, p = 0.041). Changes in gut microbiota profiles were observed at phylum, family, genus and species levels. GLP-1 secretion and variables of carbohydrate metabolism were improved. Correlations were seen between GLP-1 changes and variations within microbial community abundances, specifically Bifidobacterium adolescentis, the Lachnobacterium genus, and Coriobacteriaceae family. A conventional treatment to eradicate H. pylori could improve carbohydrate metabolism possibly in relation with an increase in GLP-1 secretion. GLP-1 secretion may be related to alterations in intestinal microbiota, specifically Lachnobacterium, B. adolescentis and Coriobacteriaceae.

298-LB: GLP-1 Secretion Enhancement after H. Pylori Eradication Treatment Is Related to Gut Microbiota Modification

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 298-LB
Author(s):  
ISABEL CORNEJO-PAREJA ◽  
GRACIA MARÍA MARTIN-NUÑEZ ◽  
ISABEL MORENO-INDIAS ◽  
FERNANDO F. CARDONA-DÍAZ ◽  
M. MAR ROCA-RODRIGUEZ ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
H Pylori

scholarly journals In VitroandIn VivoActivities of Zinc Linolenate, a Selective Antibacterial Agent againstHelicobacter pylori

2019 ◽  
Vol 63 (6) ◽  
Author(s):  
Yanqiang Huang ◽  
Xudong Hang ◽  
Xueqing Jiang ◽  
Liping Zeng ◽  
Jia Jia ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Therapeutic Potential ◽  
Combined Therapy ◽  
Peptic Ulcers ◽  
Current Standard ◽  
Gastric Diseases ◽  
Content Type ◽  
H Pylori

ABSTRACTHelicobacter pyloriis a major global pathogen, and its infection represents a key factor in the etiology of various gastric diseases, including gastritis, peptic ulcers, and gastric carcinoma. The efficacy of current standard treatment forH. pyloriinfection including two broad-spectrum antibiotics is compromised by toxicity toward the gut microbiota and the development of drug resistance, which will likely only be resolved through novel and selective antibacterial strategies. Here, we synthesized a small molecule, zinc linolenate (ZnLla), and investigated its therapeutic potential for the treatment ofH. pyloriinfection. ZnLla showed effective antibacterial activity against standard strains and drug-resistant clinical isolates ofH. pyloriin vitrowith no development of resistance during continuous serial passaging. The mechanisms of ZnLla action againstH. pyloriinvolved the disruption of bacterial cell membranes and generation of reactive oxygen species. In mouse models of multidrug-resistantH. pyloriinfection, ZnLla showedin vivokilling efficacy comparable and superior to the triple therapy approach when use as a monotherapy and a combined therapy with omeprazole, respectively. Moreover, ZnLla treatment induces negligible toxicity against normal tissues and causes minimal effects on both the diversity and composition of the murine gut microbiota. Thus, the high degree of selectivity of ZnLla forH. pyloriprovides an attractive candidate for novel targeted anti-H. pyloritreatment.

scholarly journals H. pylori eradication with antibiotic treatment causes changes in glucose homeostasis related to modifications in the gut microbiota

PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0213548 ◽  
Author(s):  
Gracia Mª Martín-Núñez ◽  
Isabel Cornejo-Pareja ◽  
Leticia Coin-Aragüez ◽  
Mª del Mar Roca-Rodríguez ◽  
Araceli Muñoz-Garach ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Antibiotic Treatment ◽  
Glucose Homeostasis ◽  
H Pylori

scholarly journals Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Seyedeh Zahra Bakhti ◽  
Saeid Latifi-Navid
Keyword(s):  
Helicobacter Pylori ◽  
Gut Microbiota ◽  
Intestinal Microbiota ◽  
Bacterial Species ◽  
Short Chain Fatty Acids ◽  
Gastric Carcinogenesis ◽  
Oncogenic Signaling ◽  
Comprehensive Overview ◽  
H Pylori ◽  
Oncogenic Signaling Pathways

AbstractChronic Helicobacter pylori infection is a critical risk factor for gastric cancer (GC). However, only 1–3 % of people with H. pylori develop GC. In gastric carcinogenesis, non-H. pylori bacteria in the stomach might interact with H. pylori. Bacterial dysbiosis in the stomach can strengthen gastric neoplasia development via generating tumor-promoting metabolites, DNA damaging, suppressing antitumor immunity, and activating oncogenic signaling pathways. Other bacterial species may generate short-chain fatty acids like butyrate that may inhibit carcinogenesis and inflammation in the human stomach. The present article aimed at providing a comprehensive overview of the effects of gut microbiota and H. pylori on the development of GC. Next, the potential mechanisms of intestinal microbiota were discussed in gastric carcinogenesis. We also disserted the complicated interactions between H. pylori, intestinal microbiota, and host in gastric carcinogenesis, thus helping us to design new strategies for preventing, diagnosing, and treating GC.

scholarly journals Dynamic changes in Antibiotic Resistance Genes and Gut Microbiota after H. Pylori Eradication Therapies

2021 ◽  
Author(s):  
LINGLING WANG ◽  
Haobin Yao ◽  
Tereasa Tong ◽  
KS Lau ◽  
Suet Yi Leung ◽  
...  
Keyword(s):  
Antibiotic Resistance ◽  
Gut Microbiota ◽  
Resistance Genes ◽  
Eradication Therapy ◽  
Antibiotic Resistance Genes ◽  
Short Term ◽  
Significant Difference ◽  
Treatment Naïve ◽  
Stool Samples ◽  
H Pylori

Abstract Background: Short-term antibiotics exposure is associated with alterations in microbiota and antibiotic resistance genes (ARGs) in the human gut. While antibiotics are critical in the successful eradication of Helicobacter pylori, the short-term and long-term impacts on the composition and quantity of antibiotics resistance genes after H. pylori eradication is unclear. This study used whole genome shotgun metagenomic of stool samples to characterize the gut microbiota and ARGs, before and after H. pylori eradication therapy. Results: Forty-four H. pylori-infected patients were recruited including 21 treatment naïve patients who received clarithromycin-based triple therapy (CLA group) and 23 patients who failed previous therapies, in which 10 received levofloxacin-based quadruple therapy [LEVO group] and 13 received other combinations [OTHER group] in the current study. Stool samples were collected at baseline (before current treatment), 6-week and 6-month after eradication therapy. At baseline, there was only a slight difference among the three groups on ARGs and gut microbiota. After eradication therapy, there was a transient but significant increase in gut ARGs 6-week post-therapy, among which the LEVO group had the most significant ARGs alteration compared to other two groups. For treatment naïve patients, those with higher ARG richness and ErmF abundance were prone to fail CLA eradication. For gut microbiota, the bacteria richness decreased at 6-week and there was a significant difference in microbiota community among the three groups at 6-week. Conclusions: Our findings demonstrated the dynamic alterations in gut microbiota and ARGs induced by different eradication therapies, which could influence the choices of antibiotics in eradication therapy.

scholarly journals A Metagenomic Insight Into the Hindgut Microbiota and Their Metabolites for Dairy Goats Fed Different Rumen Degradable Starch

2021 ◽  
Vol 12 ◽  
Author(s):  
Xiaoying Han ◽  
Xinjian Lei ◽  
Xuexin Yang ◽  
Jing Shen ◽  
Lixin Zheng ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Carbohydrate Metabolism ◽  
Immunoglobulin A ◽  
Dairy Goats ◽  
Molar Proportion ◽  
Lactating Goats ◽  
Lower Protein ◽  
Dairy Animals ◽  
Group A ◽  
Dietary Treatments

High starch diets have been proven to increase the risk of hindgut acidosis in high-yielding dairy animals. As an effective measurement of dietary carbohydrate for ruminants, studies on rumen degradable starch (RDS) and the effects on the gut microbiota diversity of carbohydrate-active enzymes (CAZymes), and Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology functional categories are helpful to understand the mechanisms between gut microbiota and carbohydrate metabolism in dairy goats. A total of 18 lactating goats (45.8 ± 1.54 kg) were randomly divided equally into three dietary treatments with low dietary RDS concentrations of 20.52% (LRDS), medium RDS of 22.15% (MRDS), and high RDS of 24.88% (HRDS) on a DM basis for 5 weeks. Compared with the LRDS and MRDS groups, HRDS increased acetate molar proportion in the cecum. For the HRDS group, the abundance of family Ruminococcaceae and genus Ruminococcaceae UCG-010 were significantly increased in the cecum. For the LRDS group, the butyrate molar proportion and the abundance of butyrate producer family Bacteroidale_S24-7, family Lachnospiraceae, and genus Bacteroidale_S24-7_group were significantly increased in the cecum. Based on the BugBase phenotypic prediction, the microbial oxidative stress tolerant and decreased potentially pathogenic in the LRDS group were increased in the cecum compared with the HRDS group. A metagenomic study on cecal bacteria revealed that dietary RDS level could affect carbohydrate metabolism by increasing the glycoside hydrolase 95 (GH95) family and cellulase enzyme (EC 3.2.1.4) in the HRDS group; increasing the GH13_20 family and isoamylase enzyme (EC 3.2.1.68) in the LRDS group. PROBIO probiotics database showed the relative gene abundance of cecal probiotics significantly decreased in the HRDS group. Furthermore, goats fed the HRDS diet had a lower protein expression of Muc2, and greater expression RNA of interleukin-1β and secretory immunoglobulin A in cecal mucosa than did goats fed the LRDS diet. Combined with the information from previous results from rumen, dietary RDS level altered the degradation position of carbohydrates in the gastrointestinal (GI) tract and increased the relative abundance of gene encoded enzymes degrading cellulose in the HRDS group in the cecum of dairy goats. This study revealed that the HRDS diet could bring disturbances to the microbial communities network containing taxa of the Lachnospiraceae and Ruminococcaceae and damage the mucus layer and inflammation in the cecum of dairy goats.

scholarly journals The impact of probiotics supplementation on gut microbiota after Helicobacter pylori eradication: a multicenter, open-label, randomised trial

2020 ◽  
Author(s):  
Bo Tang ◽  
Li Tang ◽  
Cheng Huang ◽  
Chuan Tian ◽  
Ling Chen ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gut Microbiota ◽  
Randomised Trial ◽  
Eradication Therapy ◽  
Open Label ◽  
Quadruple Therapy ◽  
Alpha And Beta Diversity ◽  
Group A ◽  
H Pylori ◽  
Group B

Abstract Background: Helicobacter pylori (H. pylori) eradication therapy may lead to the perturbation of gut microbiota. The role of probiotics in gut microbiota during eradication therapy is still debated. Design: This was a multicentre, open-label, randomised trial done at seven hospitals in China. 162 patients were enrolled, 79 patients were randomly divided into group A (bismuth quadruple therapy), and 83 patients were randomly subjected into group B (bismuth quadruple therapy supplemented with Medilac-S). Faecal samples were collected before treatment and 2 weeks, 4 weeks, 6 weeks, and 8 weeks after eradication therapy. Gut microbiota was analyzed by 16S rRNA high-throughput sequencing. This trial is complete and registered with Chinese Clinical Trial Registry (Chictr.org.cn, ChiCTR1900022116). Results: The eradication rates of group A and group B were 82.43% and 87.01%, respectively (P>0.05). Compared with baseline, alpha and beta diversity was significantly altered 2 weeks after eradication in both group A and group B, which was restored at week 8. There were no significant differences in alpha and beta diversity between the two groups. Bismuth quadruple therapy resulted in enrichment of some detrimental bacteria taxa such as Klebsiella and Streptococcus that were not recovered by week 8. Probiotics supplementation could rapidly restore the taxa levels of Klebsiella and Streptococcus by week 4 after eradication, and increase the beneficial taxa of Bacillus and Lactobacillales. Functional analysis revealed that lipopolysaccharide biosynthesis and polymyxin resistance pathways were significantly enriched after eradication therapy, while probiotics supplementation mainly enriched the cofactors and vitamins metabolism pathways. Several detrimental taxa were identified to be correlated with features of older age, alcohol use and high BMI, while probiotics supplementation could effectively restore the adverse impact in patients with these characteristics.Conclusion: Probiotics supplementation is beneficial for patients during H. pylori eradication, especially for patients with older age, alcohol drinking, and obesity, which might obtain the maximum benefits.

scholarly journals Metformin Modifies the Gut Microbiota of Mice Infected with Helicobacter pylori

2021 ◽  
Vol 14 (4) ◽  
pp. 329
Author(s):  
Marine Jauvain ◽  
Sarah Courtois ◽  
Philippe Lehours ◽  
Emilie Bessède
Keyword(s):  
Gut Microbiota ◽  
Alpha Diversity ◽  
Diversity Indices ◽  
Digestive Cancer ◽  
Pathway Expression ◽  
16S Rna ◽  
Intestinal Contents ◽  
Functional Pathway ◽  
H Pylori

Metformin is widely prescribed to treat type 2 diabetes. Diabetes patients treated with metformin have a decreased risk of cancers, including gastric cancer. Among the factors influencing digestive carcinogenesis, gut microbiota interactions have been intensively studied. Metformin exhibits direct antimicrobial activity toward Helicobacterpylori, which plays a crucial role in gastric carcinogenesis. Mice were infected with H. pylori and treated for 12 days with either metformin or phosphate-buffered saline (PBS) as a control. At the end of the treatment period, the mice were euthanized and cecal and intestinal contents and stool were collected. The gut microbiota of the three different digestive sites (stool, cecal, and intestinal contents) were characterized through 16S RNA gene sequencing. In mice infected with H. pylori, metformin significantly decreased alpha diversity indices and led to significant variation in the relative abundance of some bacterial taxa including Clostridium and Lactobacillus, which were directly inhibited by metformin in vitro. PICRUSt analysis suggested that metformin modifies functional pathway expression, including a decrease in nitrate reducing bacteria in the intestine. Metformin significantly changed the composition and predicted function of the gut microbiota of mice infected with H. pylori; these modifications could be implicated in digestive cancer prevention.

Effects of cranberry beverage on oxidative stress and gut microbiota in subjects with Helicobacter pylori infection: a randomized, double-blind, placebo-controlled trial

2021 ◽  
Author(s):  
Tao Gao ◽  
Meiling Hou ◽  
Bo Zhang ◽  
Xin Pan ◽  
Chengxia Liu ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Helicobacter Pylori ◽  
Gut Microbiota ◽  
Controlled Trial ◽  
Gastric Diseases ◽  
Oxidative Stress Biomarkers ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Stress Biomarkers ◽  
H Pylori

Helicobacter pylori-induced oxidative stress plays an important role in gastric diseases. H. pylori disturbs gut microbiota. The objective is to investigate the effects of cranberry beverages on oxidative stress biomarkers...

Sign in / Sign up

Export Citation Format

Share Document